1. Home
  2. MBBC vs VERU Comparison

MBBC vs VERU Comparison

Compare MBBC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

BUY

Current Price

$14.97

Market Cap

40.2M

Sector

Finance

ML Signal

BUY

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.35

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
VERU
Founded
1902
1971
Country
United States
United States
Employees
35
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
MBBC
VERU
Price
$14.97
$2.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
12.0K
49.5K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.94
$0.36
52 Week High
$14.64
$4.59

Technical Indicators

Market Signals
Indicator
MBBC
VERU
Relative Strength Index (RSI) 61.62 47.52
Support Level $12.93 $2.13
Resistance Level N/A $2.67
Average True Range (ATR) 0.41 0.11
MACD 0.07 -0.00
Stochastic Oscillator 99.47 21.82

Price Performance

Historical Comparison
MBBC
VERU

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: